SungHee Park

SungHee Park

Auto-generated profile, based on publicly available information

SungHee Park

The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Cell Reports
Verified
Journal Article
Open access
LULaura Urbanski
Laura Urbanski
MBMattia Brugiolo
Mattia Brugiolo
SPSungHee Park
SungHee Park
BABrittany L. Angarola
Brittany L. Angarola
NLNathan K. Leclair
Nathan K. Leclair
OAOlga Anczukow
Olga Anczukow
MYC is dysregulated in >50% of cancers, but direct targeting of MYC has been clinically unsuccessful. Targeting downstream MYC effector pathways represents an attractive alternative. MYC regulates alternative mRNA splicing, but the mechanistic links between MYC and the splicing machinery in cancer remain under-explored. Here, we identify a network of co-expressed splicing factors (SF-modules) in MYC-active breast tumors. Of these, one is a pan-cancer SF-module correlating with MYC activity across 33 tumor types. In mammary cell models, MYC activation leads to co-upregulation of pan-cancer module SFs and to changes in >4,000 splicing events. In breast cancer organoids, co-overexpression of the pan-cancer SF-module induces MYC-regulated splicing events and increases organoid size and invasiveness, while knockdown decreases organoid size. Finally, we uncover a MYC-activity pan-cancer splicing signature correlating with survival across tumor types. Our findings provide insight into the mechanisms of MYC-regulated splicing and for the development of therapeutics for MYC-driven tumors.

13 December 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
YJYukyung Jun
Yukyung Jun
YSYun-Suhk Suh
Yun-Suhk Suh
SPSungHee Park
SungHee Park
JLJieun Lee
Jieun Lee
JKJong-Il Kim
Jong-Il Kim
CLCharles Lee
Charles Lee
Alternatively spliced RNA isoforms are a hallmark of tumors, but their nature, prevalence, and clinical implications in gastric cancer have not been comprehensively characterized. We systematically profiled the splicing landscape of 83 gastric tumors and matched normal mucosa, identifying and experimentally validating eight splicing events that can classify all gastric cancers into three subtypes: epithelial-splicing (EpiS), mesenchymal-splicing (MesS), and hybrid-splicing. These subtypes were associated with distinct molecular signatures and epithelial–mesenchymal transition markers. Subtype-specific splicing events were enriched in motifs for splicing factors RBM24 and ESRP1, which were upregulated in MesS and EpiS tumors, respectively. A simple classifier based only on RNA levels of RBM24 and ESRP1, which can be readily implemented in the clinic, was sufficient to distinguish gastric cancer subtypes and predict patient survival in multiple independent patient cohorts. Overall, this study provides insights into alternative splicing in gastric cancer and the potential clinical utility of splicing-based patient classification. Significance: This study presents a comprehensive analysis of alternative splicing in the context of patient classification, molecular mechanisms, and prognosis in gastric cancer.

19 December 2024 in Cancer Research
Verified
Journal Article
Closed access
JRJill C. Rubinstein
Jill C. Rubinstein
SDSergii Domanskyi
Sergii Domanskyi
TSTodd B. Sheridan
Todd B. Sheridan
BSBrian Sanderson
Brian Sanderson
SPSungHee Park
SungHee Park
Jeffrey ChuangJeffrey Chuang
Jeffrey Chuang
Resistance of BRAF-mutant melanomas to targeted therapy arises from the ability of cells to enter a persister state, evade treatment with relative dormancy, and repopulate the tumor when reactivated. A better understanding of the temporal dynamics and specific pathways leading into and out of the persister state is needed to identify strategies to prevent treatment failure. Using spatial transcriptomics in patient-derived xenograft models, we captured clonal lineage evolution during treatment. The persister state showed increased oxidative phosphorylation, decreased proliferation, and increased invasive capacity, with central-to-peripheral gradients. Phylogenetic tracing identified intrinsic and acquired resistance mechanisms (e.g., dual-specific phosphatases, reticulon-4, and cyclin-dependent kinase 2) and suggested specific temporal windows of potential therapeutic susceptibility. Deep learning–enabled analysis of histopathologic slides revealed morphologic features correlating with specific cell states, demonstrating that juxtaposition of transcriptomics and histologic data enabled identification of phenotypically distinct populations from using imaging data alone. In summary, this study defined state change and lineage selection during melanoma treatment with spatiotemporal resolution, elucidating how choice and timing of therapeutic agents will impact the ability to eradicate resistant clones. Significance: Tracking clonal progression during treatment uncovers conserved, global transcriptional changes and local clone–clone and spatial patterns underlying the emergence of resistance, providing insights into therapy-induced tumor evolution.

17 June 2026
Verified
Other
Open access
JRJill C. Rubinstein
Jill C. Rubinstein
SDSergii Domanskyi
Sergii Domanskyi
TSTodd B. Sheridan
Todd B. Sheridan
BSBrian Sanderson
Brian Sanderson
SPSungHee Park
SungHee Park
Jeffrey ChuangJeffrey Chuang
Jeffrey Chuang
Differentially expressed genes between the boundary cluster 7 (yellow) and both its internally and externally neighboring clusters, 4 (orange) and 3 (cyan) (WM4237).